Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Other Non Operating Income: 2016-2020

Historic Other Non Operating Income for Summit Therapeutics (SMMT) over the last 2 years, with Mar 2020 value amounting to -$3.4 million.

  • Summit Therapeutics' Other Non Operating Income fell 481.17% to -$3.4 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$3.6 million, marking a year-over-year decrease of 283.74%. This contributed to the annual value of $722,000 for FY2019, which is N/A change from last year.
  • According to the latest figures from Q1 2020, Summit Therapeutics' Other Non Operating Income is -$3.4 million, which was down 512.21% from $831,864 recorded in Q4 2019.
  • Summit Therapeutics' 5-year Other Non Operating Income high stood at $1.5 million for Q4 2019, and its period low was -$3.4 million during Q1 2020.
  • Over the past 3 years, Summit Therapeutics' median Other Non Operating Income value was $95,640 (recorded in 2018), while the average stood at -$563,582.
  • Per our database at Business Quant, Summit Therapeutics' Other Non Operating Income soared by 818.49% in 2017 and then crashed by 481.17% in 2020.
  • Over the past 5 years, Summit Therapeutics' Other Non Operating Income (Quarterly) stood at -$181,728 in 2016, then skyrocketed by 818.49% to $590,389 in 2017, then crashed by 208.50% to -$640,584 in 2018, then reached $831,864 in 2019, then crashed by 481.17% to -$3.4 million in 2020.
  • Its Other Non Operating Income was -$3.4 million in Q1 2020, compared to $831,864 in Q4 2019 and $1.5 million in Q4 2019.